The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Official Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Study ID: NCT01200589
Brief Summary: This was a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6 months after completing treatment with single agent rituximab or a rituximab-containing regimen. Subjects must have attained a Complete Response or Partial Response to their last prior rituximab containing therapy lasting at least six months beyond the end of rituximab therapy. Subjects were to receive four weekly doses of single agent ofatumumab (1000 mg) or rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2 months for four additional doses. Therefore, subjects were to receive a total of eight doses of anti-CD20 antibody over 9 months. Subjects were evaluated for response after completion of the first four doses of therapy, after six doses of therapy, and after completion of study therapy. Subjects were to be followed until the end of the designated follow-up period (total study duration of 200 weeks) or until they meet the withdrawal criteria. The primary objective of the study OMB157D 2303 was to demonstrate the efficacy of Arzerra based on the primary endpoint (Progression-free survival (PFS) as assessed by the IRC) in patients with Indolent B-cell Non-Hodgkin's Lymphoma Relapsed After Rituximab-Containing Regimen. The Independent Data Monitoring Committee (IDMC) met on November 22, 2015 and recommended the termination of the study due to futility (cut-off date = 12Jun2015). The IDMC reviewed analyses results for progression free survival (PFS), overall response rate (ORR), and overall survival (OS). Novartis accepted this recommendation and the study was closed. Final analysis was performed (cut-off date =19 Dec 2016). As the study was stopped for futility, the primary objective was not met and some secondary endpoints, supportive of primary objective (Duration of Response (DOR), time to next therapy, and pharmacokinetics) were removed as secondary end points.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Novartis Investigative Site, Anchorage, Alaska, United States
Novartis Investigative Site, Gilbert, Arizona, United States
Novartis Investigative Site, Hot Springs, Arkansas, United States
Novartis Investigative Site, Greenbrae, California, United States
Novartis Investigative Site, Monterey, California, United States
Novartis Investigative Site, Pleasant Hill, California, United States
Novartis Investigative Site, Rancho Mirage, California, United States
Novartis Investigative Site, Salinas, California, United States
Novartis Investigative Site, San Diego, California, United States
Novartis Investigative Site, San Pablo, California, United States
Novartis Investigative Site, Santa Monica, California, United States
Novartis Investigative Site, New Milford, Connecticut, United States
Novartis Investigative Site, Torrington, Connecticut, United States
Novartis Investigative Site, Lakeland, Florida, United States
Novartis Investigative Site, Orlando, Florida, United States
Novartis Investigative Site, Pembroke Pines, Florida, United States
Novartis Investigative Site, Port Saint Lucie, Florida, United States
Novartis Investigative Site, West Palm Beach, Florida, United States
Novartis Investigative Site, Macon, Georgia, United States
Novartis Investigative Site, Marietta, Georgia, United States
Novartis Investigative Site, Evanston, Illinois, United States
Novartis Investigative Site, Peoria, Illinois, United States
Novartis Investigative Site, Quincy, Illinois, United States
Novartis Investigative Site, Skokie, Illinois, United States
Novartis Investigative Site, Anderson, Indiana, United States
Novartis Investigative Site, Indianapolis, Indiana, United States
Novartis Investigative Site, Ames, Iowa, United States
Novartis Investigative Site, Mount Sterling, Kentucky, United States
Novartis Investigative Site, Metairie, Louisiana, United States
Novartis Investigative Site, Shreveport, Louisiana, United States
Novartis Investigative Site, Waterville, Maine, United States
Novartis Investigative Site, Silver Spring, Maryland, United States
Novartis Investigative Site, Grand Rapids, Michigan, United States
Novartis Investigative Site, Kalamazoo, Michigan, United States
Novartis Investigative Site, Jackson, Mississippi, United States
Novartis Investigative Site, Columbia, Missouri, United States
Novartis Investigative Site, Kansas City, Missouri, United States
Novartis Investigative Site, Saint Joseph, Missouri, United States
Novartis Investigative Site, Springfield, Missouri, United States
Novartis Investigative Site, Bozeman, Montana, United States
Novartis Investigative Site, Lincoln, Nebraska, United States
Novartis Investigative Site, Lincoln, Nebraska, United States
Novartis Investigative Site, Albuquerque, New Mexico, United States
Novartis Investigative Site, Albuquerque, New Mexico, United States
Novartis Investigative Site, Lake Success, New York, United States
Novartis Investigative Site, Mount Kisco, New York, United States
Novartis Investigative Site, Greensboro, North Carolina, United States
Novartis Investigative Site, Bismarck, North Dakota, United States
Novartis Investigative Site, Canton, Ohio, United States
Novartis Investigative Site, Canton, Ohio, United States
Novartis Investigative Site, Portland, Oregon, United States
Novartis Investigative Site, Danville, Pennsylvania, United States
Novartis Investigative Site, Ephrata, Pennsylvania, United States
Novartis Investigative Site, Lancaster, Pennsylvania, United States
Novartis Investigative Site, Willow Grove, Pennsylvania, United States
Novartis Investigative Site, Chattanooga, Tennessee, United States
Novartis Investigative Site, Germantown, Tennessee, United States
Novartis Investigative Site, Knoxville, Tennessee, United States
Novartis Investigative Site, Fort Sam Houston, Texas, United States
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, Ogden, Utah, United States
Novartis Investigative Site, Salt Lake City, Utah, United States
Novartis Investigative Site, Fredericksburg, Virginia, United States
Novartis Investigative Site, Kennewick, Washington, United States
Novartis Investigative Site, Kirkland, Washington, United States
Novartis Investigative Site, Mount Vernon, Washington, United States
Novartis Investigative Site, Seattle, Washington, United States
Novartis Investigative Site, Seattle, Washington, United States
Novartis Investigative Site, Sequim, Washington, United States
Novartis Investigative Site, Spokane, Washington, United States
Novartis Investigative Site, Antwerpen, , Belgium
Novartis Investigative Site, Antwerpen, , Belgium
Novartis Investigative Site, Brugge, , Belgium
Novartis Investigative Site, Brussels, , Belgium
Novartis Investigative Site, Bruxelles, , Belgium
Novartis Investigative Site, Kortrijk, , Belgium
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Wilrijk, , Belgium
Novartis Investigative Site, Salvador, Bahía, Brazil
Novartis Investigative Site, Betim, Minas Gerais, Brazil
Novartis Investigative Site, Curitiba, Paraná, Brazil
Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil
Novartis Investigative Site, Barretos, São Paulo, Brazil
Novartis Investigative Site, Jau, São Paulo, Brazil
Novartis Investigative Site, Sao Paulo, São Paulo, Brazil
Novartis Investigative Site, Sao Paulo, São Paulo, Brazil
Novartis Investigative Site, Sao Paulo, São Paulo, Brazil
Novartis Investigative Site, Sao Paulo, São Paulo, Brazil
Novartis Investigative Site, Rio de Janeiro, , Brazil
Novartis Investigative Site, Rio de Janeiro, , Brazil
Novartis Investigative Site, Pleven, , Bulgaria
Novartis Investigative Site, Plovdiv, , Bulgaria
Novartis Investigative Site, Sofia, , Bulgaria
Novartis Investigative Site, Sofia, , Bulgaria
Novartis Investigative Site, Sofia, , Bulgaria
Novartis Investigative Site, Varna, , Bulgaria
Novartis Investigative Site, Moncton, New Brunswick, Canada
Novartis Investigative Site, Kitchener, Ontario, Canada
Novartis Investigative Site, Sherbrooke, Quebec, Canada
Novartis Investigative Site, Quebec, , Canada
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Tianjin, , China
Novartis Investigative Site, Brno, , Czechia
Novartis Investigative Site, Hradec Kralove, , Czechia
Novartis Investigative Site, Ostrava, , Czechia
Novartis Investigative Site, Praha 2, , Czechia
Novartis Investigative Site, Boulogne sur Mer Cedex, , France
Novartis Investigative Site, Clermont-Ferrand Cedex 1, , France
Novartis Investigative Site, La Roche sur Yon Cedex 9, , France
Novartis Investigative Site, Le Mans, , France
Novartis Investigative Site, Montpellier cedex 5, , France
Novartis Investigative Site, Pessac cedex, , France
Novartis Investigative Site, Budapest, , Hungary
Novartis Investigative Site, Debrecen, , Hungary
Novartis Investigative Site, Gyor, , Hungary
Novartis Investigative Site, Szeged, , Hungary
Novartis Investigative Site, Aichi, , Japan
Novartis Investigative Site, Kyoto, , Japan
Novartis Investigative Site, Miyagi, , Japan
Novartis Investigative Site, Nagasaki, , Japan
Novartis Investigative Site, Saitama, , Japan
Novartis Investigative Site, Tochigi, , Japan
Novartis Investigative Site, Tokyo, , Japan
Novartis Investigative Site, Tokyo, , Japan
Novartis Investigative Site, Busan, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Miraflores, Lima, Peru
Novartis Investigative Site, San Isidro, Lima, Peru
Novartis Investigative Site, Lima, , Peru
Novartis Investigative Site, Lima, , Peru
Novartis Investigative Site, Lima, , Peru
Novartis Investigative Site, San Juan, , Puerto Rico
Novartis Investigative Site, Bratislava, , Slovakia
Novartis Investigative Site, Kosice, , Slovakia
Novartis Investigative Site, Martin, , Slovakia
Novartis Investigative Site, Parktown, Gauteng, South Africa
Novartis Investigative Site, Athlone Park, Amanzimtoti, , South Africa
Novartis Investigative Site, Port Elizabeth, , South Africa
Novartis Investigative Site, Saxonwold, Johannesburg, , South Africa
Novartis Investigative Site, Donetsk, , Ukraine
Novartis Investigative Site, Kyiv, , Ukraine
Novartis Investigative Site, Kyiv, , Ukraine
Novartis Investigative Site, Lviv, , Ukraine
Novartis Investigative Site, Makiivka, , Ukraine
Novartis Investigative Site, Simferopil, , Ukraine
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR